Related Experiment Video
Updated: Apr 21, 2026

A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products
Published on: October 4, 2019
Systematic metabolic engineering of Escherichia coli for high-level production of pseudouridine via pathway
Jing Song1, Wei Shen2, Yuanyuan Xia2
1School of Biotechnology and Key Laboratory of Carbohydrate Chemistry and Biotechnology of Ministry of Education, Jiangnan University, Wuxi, 214122, China.
Abstract:
Pseudouridine, the C5-ribose epimer of uridine with significant biological functions and clinical applications, was efficiently produced through systematic metabolic strategy of Escherichia coli in this study. Initial overexpression of pseudouridine-5-phosphate glycosylase gene psuG and alkaline phosphatase gene YjjG in E. coli pRSFDuet-1-YjjG-psuG yielded 0.43 g L-1 pseudouridine, which increased 8.56-fold with 5 g L-1 uridine supplementation. Subsequent deletion of thrA, psuT, argF, and pepA enhanced titer by 1.29-fold in E. coli ΔthrAΔpsuTΔargFΔpepA pRSFDuet-1-YjjG-psuG, while ribonucleoside hydrolase gene rihA overexpression boosted titer to 5.57 g L-1. Further optimization through deleting the uridine kinase gene udk and overexpressing the ribokinase gene rbsK in strain E. coli ΔthrAΔpsuTΔargFΔpepAΔudkΔudpΔppnp pRSFDuet-1-YjjG-psuG pCDFDuet-1-rihA-rbsK achieved 6.23 g L-1 pseudouridine, increasing to 11.34 g L-1 with two-stage uridine feeding. Fed-batch fermentation in a 5-L bioreactor yielded a record 102.2 g L-1 pseudouridine. This work provides an efficient and scalable bioprocess for industrial pseudouridine manufacturing to meet the growing demands of mRNA-based applications.
More Related Videos
10:41The Logic, Experimental Steps, and Potential of Heterologous Natural Product Biosynthesis Featuring the Complex Antibiotic Erythromycin A Produced Through E. coli
Published on: January 13, 2013
10:09Inducible T7 RNA Polymerase-mediated Multigene Expression System, pMGX
Published on: June 27, 2017
Related Concept Videos
Bioreactor Controls-III
Production of Pharmaceuticals
Upstream Processing
Biosynthesis in Bacteria
Stringent Response in E. coli
Other Glycolytic Pathways